Biologics are complex, high-cost treatments derived from living systems, used for immune-related disorders. Biosimilars are more affordable alternatives that are highly similar to biologics, with no significant clinical differences. The FDA supports biosimilar development to reduce costs, and various financial aids are available to help patients access these treatments. Join us as we discuss these important topics.

CME Credit Available: https://uiowa.cloud-cme.com/course/courseoverview?P=0&EID=67816

Host: Gerard Clancy, MD Senior Associate Dean for External Affairs Professor of Psychiatry and Emergency Medicine University of Iowa Carver College of Medicine

Guests: Brittany Bettendorf, MD Associate Professor of Rheumatology University of Iowa Carver College of Medicine

Ashlyn Johnson, PharmD Pharmacy Specialist Inflammatory Bowel Disease Treatment Team University of Iowa Hospitals & Clinics

Financial Disclosures: Dr. Gerard Clancy, his guests and the members of the planning committee for Rounding@IOWA have no relevant financial relationships to disclose.

CME Credit Designation: The University of Iowa Roy J. and Lucille A. Carver College of Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist: The University of Iowa Roy J. and Lucille A. Carver College of Medicine designates this knowledge-based activity for a maximum of 0.75 ACPE contact hours. Credit will be uploaded to the NABP CPE Monitor within 60 days after the activity completion. Pharmacists must provide their NABP ID and DOB (MMDD) to receive credit. UAN: JA0000310-0000-24-070-H01-P

Other Health Care Providers: A certificate of completion will be available after successful completion of the course. (It is the responsibility of licensees to determine if this continuing education activity meets the requirements of their professional licensure board.)